

Poststelle (BMJV)

Von: Joerg Thomaier <[redacted]>
Gesendet: Mittwoch, 28. September 2016 09:41
An: Maas, Heiko (Minister)
Cc: Poststelle (BMJV)
Betreff: Joint Industry Letter - Unitary Patent and Unified Patent Court
Anlagen: JointIndustryLetter.pdf

Bundesministerium der Justiz und für Verbraucherschutz	
Abl. III	Ref. B 9
28.09.2016 12:45	
Anlagen	gehandelt fesch Doppel

Dear Mr Maas,

Please find attached a joint letter of pharmaceutical companies and associations. I am writing to you on behalf of the undersigning companies which found it timely to give a clear message in support of the unitary patent system and urge that it should enter into force as planned.

Yours sincerely,
Jörg Thomaier

Dr. Jörg Thomaier
 Bayer Intellectual Property GmbH
 Geb. 4865, R. 437
 Creative Campus Monheim
 Alfred-Nobel-Straße 10
 D-40789 Monheim
 Phone: +49 2173 38 [redacted]
 Fax: +49 2173 38 969 [redacted]
 E-Mail: [redacted]
 Web: <http://www.bayer.com>

Managing Directors: Joerg Thomaier | Michael Reinartz
 Place of Business: Monheim am Rhein | Amtsgericht Düsseldorf, HRB 67604

TIB4

GG	AE	BER	v. Abg.	Abl.			
Bundesministerium der Justiz und für Verbraucherschutz							
Eingang:		28. Sep. 2016					
Ministerbüro							
Min.	PSI J	PSIV	St J	StV	LM	PR	PRÖA

Herrn Kardorfer (An?)

PK 7110

2 dA U 14/10

September 28th, 2016

Joint Industry Letter - Unitary Patent and Unified Patent Court

The undersigned companies and associations in the pharmaceutical sector hereby make the following joint statement regarding the Unitary Patent package that is the Unitary Patent and the Unified Patent Court. Our companies are committed to research, development and manufacture in Europe of medicinal products for human use.

The pharmaceutical industry is highly regulated. The development of a new medicine and the need for market authorisation to bring a new medicine to the market takes many years and entails very significant costs, without any certainty of a positive outcome. Therefore, the pharmaceutical industry is heavily dependent on an effective patent system protecting its innovations for a certain period of time.

The introduction of the Unitary Patent and the Unified Patent Court will significantly simplify the patent system in Europe and reduce the costs for obtaining, maintaining and enforcing patents. We support and welcome this reform.

The governmental, legal and practical preparations needed for the reform are advanced or finalised within the participating States, in the Select Committee and in the Preparatory Committee, as well as on the side of industry. Very large efforts have led to this present stage.

In the wake of the political unrest seen in Europe in the summer, we find it timely to give a clear message to responsible politicians that we, the signing companies and industry associations, welcome the new patent system and urge that it should enter into force as planned.

The attractiveness of the system would increase with a long-term participation of the United Kingdom. Therefore we also urge that solutions for such inclusiveness are considered.

Very truly yours,

The undersigning pharmaceutical companies and associations



Bayer AG, Germany



**Boehringer
Ingelheim**

Boehringer Ingelheim GmbH,
Germany

Merck

Merck KGaA, Germany



novo nordisk®

Novo Nordisk A/S, Denmark

SANOFI 

Sanofi S.A., France



Takeda Pharmaceuticals
International AG, Switzerland



Union Chimique Belge, UCB S.A.,
Belgium



The research-based pharmaceutical industry

Swedish Association of the
Pharmaceutical Industry, Sweden